Mandate

Vinge advises Expedition Growth Capital in connection with Storykit’s USD 10 million investment round

Vinge advises Expedition Growth Capital in connection with Storykit’s investment round of USD 10 million led by Expedition Growth Capital. The investment in Storykit is Expedition Growth Capital’s first investment in the Nordics.

Serving large and medium sized enterprises, Storykit is leveraging artificial intelligence enabling its users to create video and tell stories on social platforms, and has quickly grown to become the leading video creator in the Nordics as well as recently expanded into several European markets. With the new funding, they will accelerate innovation and expansion at an even higher pace.

Expedition Growth Capital is a USD 200+ million London-based growth equity fund, focused solely on investing in fast growing and capital efficient B2B software companies in Europe and Israel, and this is Expedition Growth Capital’s first investment in the Nordics.

Vinge’s team consisted of Karl Klackenberg, Johan Larsson, Milad Kamali and Nina Gransäter (M&A), Stojan Arnerstål (IPR), Lisa Hörnqvist (Commercial Agreements) and Veronika Garemark (Employment).

 

Related

Vinge advises OsteoCentric on the public offer for Integrum

OsteoCentric Oncology and Bone Anchored Prostheses, LLC, a subsidiary of OsteoCentric Technologies, Inc., has made a public offer for all shares in Integrum AB (publ). The offer values all shares in Integrum at approximately SEK 939 million.
July 23, 2025

Vinge advises Investor on its co-investment in the SEK 55 billion public offer for Fortnox led by EQT X

Vinge advises Investor AB (publ) (“Investor”) on its co-investment in the public offer for Fortnox AB (publ) (“Fortnox”) led by EQT X together with First Kraft AB (owned by Olof Hallrup), acting through Omega II AB (“Omega II”). Fortnox offers vital software infrastructure to small and medium-sized companies in Sweden with a track record of profitable growth.
July 22, 2025

Vinge advises Cantargia in connection with the sale of immunology program CAN10

Vinge advises Cantargia AB (publ) in connection with the sale of its early-clinical stage IL1RAP immunology program CAN10 to the Japanese healthcare company Otsuka Pharmaceutical.
July 21, 2025